Due to a higher incidence of thrombosis in patients (sorry, sheep), the study team concluded that they cannot currently recommend the use of MSCs in combination with ECMO.
Makes you wonder why the hell CYP put this announcement out in the first place.
- Forums
- ASX - By Stock
- Ann: Cynata MSCs beneficial in preclinical ARDS study
Due to a higher incidence of thrombosis in patients (sorry,...
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
25.5¢ |
Change
0.005(2.00%) |
Mkt cap ! $45.80M |
Open | High | Low | Value | Volume |
25.5¢ | 25.5¢ | 25.5¢ | $313 | 1.229K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 22209 | 25.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 36715 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20209 | 0.250 |
2 | 49573 | 0.245 |
2 | 102000 | 0.240 |
1 | 100000 | 0.235 |
2 | 15173 | 0.230 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 36715 | 1 |
0.265 | 8119 | 2 |
0.270 | 30000 | 1 |
0.290 | 1900 | 1 |
0.295 | 183892 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |